Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma
Version of Record online: 22 JAN 2008
Copyright © 2008 Wiley Periodicals, Inc.
Head & Neck
Volume 30, Issue 7, pages 863–867, July 2008
How to Cite
Chua, D. T. T., Wei, W. I., Wong, M. P., Sham, J. S. T., Nicholls, J. and Au, G. K. H. (2008), Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck, 30: 863–867. doi: 10.1002/hed.20792
- Issue online: 9 JUN 2008
- Version of Record online: 22 JAN 2008
- Manuscript Accepted: 24 OCT 2007
- nasopharyngeal carcinoma;
- epidermal growth factor receptor;
- distant metastases
This single-center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinum-based chemotherapy.
Patients with recurrent and metastatic NPC who had treatment failure with at least 2 lines of chemotherapy including platinum were given gefitinib at a fixed dose of 250 mg daily. Treatment was continued until the patient experienced unacceptable side effects or disease progression.
Nineteen patients were enrolled, having had treatment failure with a median of 2 chemotherapy regimens. Treatment was well tolerated, and only grades 1 to 2 adverse events were observed. None of the patients achieved partial or complete response. Median time-to-progression was 4 months, and median overall survival was 16 months.
Gefitinib was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in NPC is not recommended outside the context of clinical trial. © 2008 Wiley Periodicals, Inc. Head Neck, 2008